- Conditions
- Primary Immune Deficiency
- Interventions
- IgPro20
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 2 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 4
- States / cities
- Centennial, Colorado • North Palm Beach, Florida • Indianapolis, Indiana + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 461
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Immunologic Deficiency Syndromes
- Interventions
- GC5107
- Biological
- Lead sponsor
- Green Cross Corporation
- Industry
- Eligibility
- 2 Years to 70 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 10
- States / cities
- Centennial, Colorado • North Palm Beach, Florida • Plymouth, Minnesota + 6 more
- Conditions
- DENV-3 Controlled Human Infection Model
- Interventions
- AV-1 100 mg, AV-1 300 mg, AV-1 900 mg, Placebo
- Drug
- Lead sponsor
- AbViro LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Burlington, Vermont
- Conditions
- Advanced Solid Tumor
- Interventions
- YL201, YL201 and atezolizumab
- Drug
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 19
- States / cities
- Fair Oaks, California • La Jolla, California • Lone Tree, Colorado + 16 more
- Conditions
- Neuroblastoma
- Interventions
- beta-glucan, monoclonal antibody 3F8, immunohistochemistry staining method, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 0 Years to 120 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Sepsis
- Interventions
- IVIG, Placebo
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- Up to 72 Hours
- Enrollment
- 2,416 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1988 – 1991
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 5 more
- Conditions
- Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations, Anti-myostatin
- Interventions
- Apitegromab, Placebo
- Drug
- Lead sponsor
- Scholar Rock, Inc.
- Industry
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 23 more
- Conditions
- Highly Sensitized Prospective Kidney Transplant Recipients
- Interventions
- daratumumab, belatacept, Bone marrow aspiration
- Biological · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- BNT116, Cemiplimab, Docetaxel, Carboplatin, Paclitaxel, BNT316, anti-B7-H3 antibody conjugated to topoisomerase I inhibitor, anti-HER3 antibody conjugated to topoisomerase I inhibitor, Bispecific antibody for PD-L1 and VEGF-A, Osimertinib, ALK-inhibitor or RET-inhibitor
- Biological · Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 6
- States / cities
- Lexington, Kentucky • Louisville, Kentucky • Baltimore, Maryland + 3 more
- Conditions
- Healthy
- Interventions
- NM8074, Placebo
- Drug
- Lead sponsor
- NovelMed Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Solid Tumor
- Interventions
- AT03-65
- Drug
- Lead sponsor
- Axcynsis Therapeutics Pte Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Denver, Colorado • New Haven, Connecticut • Portland, Oregon + 1 more
- Conditions
- Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
- Interventions
- MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX
- Drug · Combination Product
- Lead sponsor
- Merus B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 31
- States / cities
- La Jolla, California • Los Angeles, California • San Diego, California + 25 more
- Conditions
- Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma
- Interventions
- AFM13, AB-101, Cyclophosphamide, Fludarabine, Interleukin-2
- Drug
- Lead sponsor
- Affimed GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Duarte, California • Orange, California + 11 more
- Conditions
- Colorectal Neoplasm
- Interventions
- DS-8201a
- Drug
- Lead sponsor
- Daiichi Sankyo Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 9
- States / cities
- Duarte, California • Los Angeles, California • Santa Monica, California + 6 more
- Conditions
- Hepatocellular Carcinoma (HCC), Solid Tumors
- Interventions
- BAY3630942, BAY3547922
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 1 more
- Conditions
- Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
- Interventions
- MEDI-573 (1 of 3 doses), Sorafenib
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- Oxnard, California • Golden Springs, Colorado • Las Vegas, Nevada
- Conditions
- End-Stage Renal Disease, Kidney Transplantation
- Interventions
- Intravenous immune globulin (IVIG)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2003
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- Primary Immune Deficiency
- Interventions
- GC5107
- Biological
- Lead sponsor
- GC Biopharma Corp
- Industry
- Eligibility
- 2 Years to 16 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Centennial, Colorado • Dallas, Texas + 2 more
- Conditions
- Human Immunodeficiency Virus (HIV), HIV Infection, HIV-1
- Interventions
- ABBV-181, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 15
- States / cities
- Bakersfield, California • Los Angeles, California • San Francisco, California + 11 more
- Conditions
- Healthy Volunteers
- Interventions
- TAK-881, HyQvia, SC Investigational Needle Sets
- Biological · Device
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Interventions
- Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
- Drug
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more
- Conditions
- HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
- Interventions
- JK07
- Drug
- Lead sponsor
- Salubris Biotherapeutics Inc
- Industry
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Tulsa, Oklahoma
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
- Interventions
- SX-682, Nivolumab Injectable Product
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Breast Cancer, Metastatic Cancer
- Interventions
- capecitabine, cyclophosphamide, doxorubicin hydrochloride, gemcitabine hydrochloride, lapatinib ditosylate, paclitaxel, vinorelbine ditartrate, Trastuzumab
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 2
- States / cities
- New York, New York • Cleveland, Ohio